Supreme Court of the United States · Official docket →
Biogen International GmbH, et al. v. Mylan Pharmaceuticals Inc.
Paid petition · United States Court of Appeals for the Federal Circuit, No. 2020-1933 · judgment November 30, 2021
Before the decision, modestly above the 4.1% base rate. The model weighted this up for counsel who has won certiorari before, a dissent in the court below (flagged in the petition), and a Federal Circuit decision below, and down for a business respondent.
Question presented
J. MICHAEL JAKES JAMES B. MONROE PAUL W. BROWNING JASON L. ROMRELL FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP 901 New York Ave., NW Washington, DC 20001 (202) 408-4000
Counsel of record
For petitioner
Seth P. Waxman
Wilmer Cutler Pickering Hale and Dorr LLP
For respondent
Nathan Kip Kelley
Perkins Coie LLP
Case
Conference history
Distributed for 1 conference
Amicus briefs
3 cert-stage
Proceedings
- Oct 03 2022Petition DENIED.
- Aug 31 2022DISTRIBUTED for Conference of 9/28/2022.
- Aug 30 2022Reply of petitioners Biogen International GmbH and Biogen MA Inc. filed. (Distributed)
- Aug 15 2022Brief of respondent Mylan Pharmaceuticals Inc. in opposition filed.
- Jul 15 2022Brief amici curiae of Pharmaceutical Research and Manufacturers of America, et al.
- Jul 14 2022Brief amicus curiae of New England Legal Foundation filed.
- Jul 11 2022Brief amicus curiae of Chemistry and the Law Division of the American Chemical Society filed.
- Jul 01 2022Motion to extend the time to file a response is granted and the time is extended to and including August 15, 2022.
- Jun 30 2022Motion to extend the time to file a response from July 15, 2022 to August 15, 2022, submitted to The Clerk.
- Jun 14 2022Petition for a writ of certiorari filed. (Response due July 15, 2022)